How India Exports Amlodipine to the World

Amlodipine, a widely used antihypertensive agent, has been the subject of numerous Abbreviated New Drug Applications (ANDAs) approved by the U.S. Food and Drug Administration (FDA). The FDA's Orange Book lists multiple approved generic versions of amlodipine, indicating a well-established presence in the U.S. market. Notably, in March 2025, the FDA approved an ANDA for amlodipine tablets submitted by a leading Indian pharmaceutical company, further solidifying India's role as a key supplier of this medication to the United States.

The regulatory pathway for generic drugs like amlodipine involves demonstrating bioequivalence to the reference listed drug, ensuring consistent quality, efficacy, and safety. Given the substantial number of active Indian exporters—599 as per TransData Nexus's proprietary trade data—compliance with FDA regulations is paramount. Import alerts, which can be issued for violations such as manufacturing deficiencies or mislabeling, serve as critical tools for the FDA to prevent non-compliant products from entering the U.S. market. As of March 2026, there are no active import alerts specifically targeting amlodipine products from India, reflecting the adherence of Indian manufacturers to FDA standards.

In the European Union (EU) and the United Kingdom (UK), marketing authorization for amlodipine is governed by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Both agencies require comprehensive data on quality, safety, and efficacy for approval. EU Good Manufacturing Practice (GMP) guidelines, which are harmonized across member states, mandate stringent quality control measures. Indian manufacturers exporting to these regions must ensure compliance with these GMP standards to maintain market access.

Amlodipine is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The 24th edition of this list, published in September 2025, continues to feature amlodipine, reflecting its critical role in managing hypertension and related cardiovascular conditions. Additionally, amlodipine formulations are standardized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality benchmarks across different markets.

In India, amlodipine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the ceiling price of essential medicines to ensure affordability. As of January 2026, the ceiling price for amlodipine tablets has been set, reflecting the government's commitment to making essential medicines accessible. For exports, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) for certain pharmaceutical products; however, amlodipine is generally exempt from such requirements, facilitating its export.

The primary patents for amlodipine have expired, leading to a competitive generic market. This expiration has enabled numerous manufacturers, including those from India, to produce and export generic versions, contributing to the widespread availability and affordability of the drug globally.

In May 2025, the NPPA revised the ceiling price for amlodipine tablets, reducing it by 5% to enhance affordability for patients. In August 2025, the EMA issued a new guideline on the bioequivalence requirements for generic amlodipine products, aiming to streamline the approval process and ensure consistent therapeutic outcomes. In October 2025, the WHO updated its Good Manufacturing Practices guidelines, emphasizing stricter quality control measures for cardiovascular drugs, including amlodipine, to ensure global supply chain integrity.

These developments highlight the dynamic regulatory environment surrounding amlodipine, with ongoing efforts to balance accessibility, affordability, and quality in both domestic and international markets.

India's pharmaceutical industry, renowned as the "pharmacy of the world," heavily relies on imports for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 60–70% of these critical inputs are sourced from China. This dependency poses significant risks, as any disruption in the supply chain from China can adversely affect the production of APIs, including those for Amlodipine.

Recent analyses indicate that 58% of KSMs used for U.S.-approved APIs are solely sourced from a single country, underscoring the vulnerability of the supply chain. Such concentration increases the risk of supply interruptions due to geopolitical tensions, trade disputes, or other unforeseen events.

Our proprietary trade data from 2022 to 2026 reveals a high concentration in Amlodipine exports from India. The top five exporters account for 98.5% of the total export value, with CIPLA LIMITED alone contributing 94.2% ($10,833.0M USD). This significant concentration indicates a substantial single-source risk, as any operational or regulatory issues affecting CIPLA LIMITED could disrupt the global supply of Amlodipine.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce reliance on imports. While this initiative is a positive step, its impact on diversifying the supplier base for Amlodipine remains to be fully realized.

The ongoing geopolitical tensions in the Middle East, particularly the closure of the Strait of Hormuz since February 28, 2026, have severely disrupted global shipping routes. This strait is a critical chokepoint for global energy trade, and its closure has led to significant delays and increased shipping costs. Additionally, the Red Sea has experienced heightened security threats, further complicating maritime logistics.

These disruptions have a cascading effect on the pharmaceutical supply chain, potentially delaying the export of Amlodipine from India to key markets. The increased transit times and costs can lead to supply shortages and elevated prices in destination countries.

• Diversify API and KSM Sources: Encourage Indian pharmaceutical manufacturers to source APIs and KSMs from multiple countries to reduce dependency on a single supplier.

• Strengthen Domestic Production: Accelerate the implementation and expansion of the PLI scheme to enhance domestic manufacturing capabilities for APIs and KSMs.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to identify potential disruptions early and develop contingency plans.

• Develop Alternative Shipping Routes: Explore and invest in alternative maritime routes and logistics solutions to mitigate the impact of geopolitical disruptions.

• Establish Strategic Reserves: Create and maintain strategic reserves of critical pharmaceuticals like Amlodipine to buffer against supply chain interruptions.

RISK_LEVEL: HIGH